Paclitaxel Treatment Options in Cincinnati, OH

A collection of 222 research studies where Paclitaxel is the interventional treatment. These studies are located in the Cincinnati, OH. Paclitaxel is used for conditions such as Breast Cancer, Ovarian Cancer and Non-Small Cell Lung Cancer.

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Chronic Cough Research Study

Recruiting

Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!

Conditions:

Chronic Cough

Refractory or Unexplained Chronic Cough

Cough

Asthma

Sinusitis

Learn More

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Featured Trial

Stroke Clinical Study

Recruiting

A clinical study for people that suffer with Stroke

Conditions:

Stroke

Learn More

MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors

NCT06586515

Recruiting

The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/17/2025

Locations: University of Cincinnati (UC) - Cancer Institute, Cincinnati, Ohio +1 locations

Conditions: Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer

Learn More ›

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

NCT06018337

Recruiting

The goal of this clinical trial is to assess the efficacy of DB-1303/BNT323 compared with investigator's choice chemotherapy in terms of progression-free survival (PFS) by blinded independent central review (BICR) in the HR+, HER2-low (immunohistochemistry \[IHC\]2+/in situ hybridization \[ISH\]- and IHC 1+) population.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/16/2025

Locations: Research Site 1138-0, Akron, Ohio +1 locations

Conditions: Metastatic Breast Cancer

Learn More ›

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

NCT06625320

Recruiting

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard(s) of care (SOC) treatment.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/15/2025

Locations: University of Cincinnati Medical Center, Cincinnati, Ohio

Conditions: Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma

Learn More ›

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

NCT06445062

Recruiting

The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current subprotocols include the following: Subprotocol A: RMC-6236 + 5-fluorouracil-based regimens Subprotocol B: RMC-6236 + cetuximab with or without mFOLFOX6 Subprotocol C: RMC-6236 + gemcitabine + nab-paclitaxel Subprotocol D: RMC-9805 with or without RMC-6236 +... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/15/2025

Locations: University of Cincinnati Medical Center, Cincinnati, Ohio

Conditions: Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC, Gastrointestinal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma

Learn More ›

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer

NCT05624996

Recruiting

This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or osimertinib) versus the usual treatment alone in treating patients with non-small cell lung cancer that has spread to nearby tissue or lymph nodes (locally advanced) and cannot be treated by surgery (inoperable). SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. IGRT is a type of radiation that uses a computer to create a picture of the tumor, to help guide the radiation beam during therapy, making it more accurate and causing less damage to healthy tissue. Usual chemotherapy used in this trial consists of combinations of the following drugs: cisplatin, carboplatin, paclitaxel, nab-paclitaxel, pemetrexed, and etoposide. Cisplatin and carboplatin are in a class of medications known as platinum-containing compounds. Cisplatin works by killing, stopping, or slowing the growth of tumor cells. Carboplatin works in a way similar to the anticancer drug cisplatin but may be better tolerated than cisplatin. Carboplatin works by killing, stopping, or slowing the growth of tumor cells as well. Paclitaxel is in a class of medications called antimicrotubule agents. It works by stopping the growth and spread of tumor cells. Nab-paclitaxel is an albumin-stabilized nanoparticle formulation of paclitaxel which may have fewer side effects and work better than other forms of paclitaxel. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by blocking the action of a certain substance in the body that may help tumor cells multiply. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and deoxyribonucleic acid (DNA) repair and may kill tumor cells. Immunotherapy with durvalumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Osimertinib is in a class of medications called kinase inhibitors. It works by blocking the action of a protein called EGFR that signals cancer cells to multiply. This helps slow or stop the spread of tumor cells. Adding SBRT to the usual treatment of IGRT with chemotherapy and immunotherapy may be more effective at treating patients with locally-advanced non-small cell lung cancer than giving the usual treatment alone. Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/14/2025

Locations: Cleveland Clinic Akron General, Akron, Ohio +25 locations

Cleveland Clinic Akron General, Akron, Ohio

UH Seidman Cancer Center at UH Avon Health Center, Avon, Ohio

UHHS-Chagrin Highlands Medical Center, Beachwood, Ohio

Cleveland Clinic Mercy Hospital, Canton, Ohio

Aultman Health Foundation, Canton, Ohio

Miami Valley Hospital South, Centerville, Ohio

University of Cincinnati Cancer Center-UC Medical Center, Cincinnati, Ohio

Case Western Reserve University, Cleveland, Ohio

Riverside Methodist Hospital, Columbus, Ohio

Grant Medical Center, Columbus, Ohio

Doctors Hospital, Columbus, Ohio

Miami Valley Hospital, Dayton, Ohio

Premier Blood and Cancer Center, Dayton, Ohio

Dayton Physician LLC - Englewood, Dayton, Ohio

Miami Valley Hospital North, Dayton, Ohio

Delaware Health Center-Grady Cancer Center, Delaware, Ohio

Grady Memorial Hospital, Delaware, Ohio

Dublin Methodist Hospital, Dublin, Ohio

Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio

Miami Valley Cancer Care and Infusion, Greenville, Ohio

OhioHealth Mansfield Hospital, Mansfield, Ohio

OhioHealth Marion General Hospital, Marion, Ohio

UH Seidman Cancer Center at Lake Health Mentor Campus, Mentor, Ohio

Mercy Health - Perrysburg Hospital, Perrysburg, Ohio

Upper Valley Medical Center, Troy, Ohio

University of Cincinnati Cancer Center-West Chester, West Chester, Ohio

Conditions: Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8

Learn More ›

Study of Novel Treatment Combinations in Patients With Lung Cancer

NCT05633667

Recruiting

The goal of this platform clinical trial is to test how well novel treatment combinations work in participants with lung cancer. Substudy-01 will compare the different novel combinations versus standard of care in participants with metastatic (cancer that has spread) non-small-cell lung cancer (NSCLC) who have not been treated before. Substudy-02 will compare the different novel combination versus standard of care in participants with cancer that has progressed after receiving previous treatment... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/11/2025

Locations: Oncology Hematology Care Clinical Trials, LLC,Substudy-01, Cincinnati, Ohio +1 locations

Conditions: Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer

Learn More ›

A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer

NCT01358877

Completed

This randomized, double-blind, placebo-controlled, two-arm study will assess the safety and efficacy of pertuzumab in addition to chemotherapy plus trastuzumab as adjuvant therapy in participants with operable HER2-positive primary breast cancer. This study will be carried out in collaboration with the Breast International Group (BIG).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/11/2025

Locations: Oncology Hematology Care Inc, Cincinnati, Ohio +3 locations

Conditions: Breast Cancer

Learn More ›

Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

NCT04205968

Recruiting

This phase II trial studies how well ramucirumab and paclitaxel or the FOLFIRI regimen (leucovorin calcium, fluorouracil, and irinotecan hydrochloride) work in treating patients with small bowel cancers that have spread extensively to other anatomic sites (advanced) or are no longer responding to treatment (refractory). Ramucirumab is a monoclonal antibody that attaches to and inhibits a molecule called VEGFR-2. This may restrain new blood vessel formation therefore reducing nutrient supply to t... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/09/2025

Locations: Indu and Raj Soin Medical Center, Beavercreek, Ohio +31 locations

Indu and Raj Soin Medical Center, Beavercreek, Ohio

Saint Elizabeth Boardman Hospital, Boardman, Ohio

Dayton Physicians LLC-Miami Valley South, Centerville, Ohio

Miami Valley Hospital South, Centerville, Ohio

Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio

Oncology Hematology Care Inc-Kenwood, Cincinnati, Ohio

Bethesda North Hospital, Cincinnati, Ohio

TriHealth Cancer Institute-Westside, Cincinnati, Ohio

TriHealth Cancer Institute-Anderson, Cincinnati, Ohio

Miami Valley Hospital, Dayton, Ohio

Dayton Physician LLC-Miami Valley Hospital North, Dayton, Ohio

Miami Valley Hospital North, Dayton, Ohio

Armes Family Cancer Center, Findlay, Ohio

Blanchard Valley Hospital, Findlay, Ohio

Orion Cancer Care, Findlay, Ohio

Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio

Dayton Physicians LLC-Atrium, Franklin, Ohio

Dayton Physicians LLC-Wayne, Greenville, Ohio

Wayne Hospital, Greenville, Ohio

Greater Dayton Cancer Center, Kettering, Ohio

First Dayton Cancer Care, Kettering, Ohio

Kettering Medical Center, Kettering, Ohio

Toledo Clinic Cancer Centers-Maumee, Maumee, Ohio

Mercy Health Perrysburg Cancer Center, Perrysburg, Ohio

Springfield Regional Cancer Center, Springfield, Ohio

Springfield Regional Medical Center, Springfield, Ohio

Mercy Health - Saint Anne Hospital, Toledo, Ohio

Toledo Clinic Cancer Centers-Toledo, Toledo, Ohio

Dayton Physicians LLC - Troy, Troy, Ohio

Upper Valley Medical Center, Troy, Ohio

Saint Joseph Warren Hospital, Warren, Ohio

Saint Elizabeth Youngstown Hospital, Youngstown, Ohio

Conditions: Metastatic Small Intestinal Adenocarcinoma, Stage III Small Intestinal Adenocarcinoma AJCC v8, Stage IIIA Small Intestinal Adenocarcinoma AJCC v8, Stage IIIB Small Intestinal Adenocarcinoma AJCC v8, Stage IV Small Intestinal Adenocarcinoma AJCC v8

Learn More ›

Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma

NCT04594772

Active Not Recruiting

The purpose of this study is to determine if neoadjuvant therapy to increases resection rate for pancreatic adenocarcinoma.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/01/2025

Locations: University of Cincinnati Medical Center, Cincinnati, Ohio

Conditions: Pancreas Cancer

Learn More ›

A Phase 1/2 Study of FS118 in Patients With Advanced Malignancies

NCT03440437

Terminated

This study will be conducted in adult participants diagnosed with advanced tumors to characterize the safety, tolerability, pharmacokinetics (PK), and activity of FS118. This is a Phase 1/2, multi-center, open-label, multiple-dose, first-in-human study, designed to systematically assess safety and tolerability, to identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) for FS118 in participants with advanced tumors and to determine the efficacy of FS118 in participants w... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/27/2025

Locations: University of Cincinnati, Cincinnati, Ohio

Conditions: Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck

Learn More ›

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

NCT01275677

Completed

This randomized phase III clinical trial studies chemotherapy with or without trastuzumab after surgery to see how well they work in treating women with invasive breast cancer. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) and giving chemotherapy after surgery may kill more tumor cells. Monoclonal antibodies,... Read More

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

06/25/2025

Locations: Summa Health System - Akron Campus, Akron, Ohio +97 locations

Summa Health System - Akron Campus, Akron, Ohio

Summa Health System - Barberton Campus, Barberton, Ohio

Cleveland Clinic Cancer Center Beachwood, Beachwood, Ohio

UHHS-Chagrin Highlands Medical Center, Beachwood, Ohio

Mary Rutan Hospital, Bellefontaine, Ohio

Strecker Cancer Center-Belpre, Belpre, Ohio

Toledo Clinic Cancer Centers-Bowling Green, Bowling Green, Ohio

Aultman Health Foundation, Canton, Ohio

Miami Valley Hospital South, Centerville, Ohio

Geauga Hospital, Chardon, Ohio

Adena Regional Medical Center, Chillicothe, Ohio

Oncology Hematology Care Inc-Eden Park, Cincinnati, Ohio

Oncology Hematology Care Inc-Mercy West, Cincinnati, Ohio

The Christ Hospital, Cincinnati, Ohio

University of Cincinnati Cancer Center-UC Medical Center, Cincinnati, Ohio

Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio

Oncology Hematology Care Inc-Anderson, Cincinnati, Ohio

Oncology Hematology Care Inc-Kenwood, Cincinnati, Ohio

Bethesda North Hospital, Cincinnati, Ohio

Oncology Hematology Care Inc-Blue Ash, Cincinnati, Ohio

TriHealth Cancer Institute-Westside, Cincinnati, Ohio

TriHealth Cancer Institute-Anderson, Cincinnati, Ohio

Case Western Reserve University, Cleveland, Ohio

MetroHealth Medical Center, Cleveland, Ohio

Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland, Ohio

Cleveland Clinic Foundation, Cleveland, Ohio

North Coast Cancer Care-Clyde, Clyde, Ohio

Ohio State University Comprehensive Cancer Center, Columbus, Ohio

Mount Carmel East Hospital, Columbus, Ohio

Columbus Oncology and Hematology Associates Inc, Columbus, Ohio

Riverside Methodist Hospital, Columbus, Ohio

Columbus NCI Community Oncology Research Program, Columbus, Ohio

Grant Medical Center, Columbus, Ohio

The Mark H Zangmeister Center, Columbus, Ohio

Mount Carmel Health Center West, Columbus, Ohio

Doctors Hospital, Columbus, Ohio

Grandview Hospital, Dayton, Ohio

Good Samaritan Hospital - Dayton, Dayton, Ohio

Miami Valley Hospital, Dayton, Ohio

Miami Valley Hospital North, Dayton, Ohio

Dayton NCI Community Oncology Research Program, Dayton, Ohio

Delaware Health Center-Grady Cancer Center, Delaware, Ohio

Delaware Radiation Oncology, Delaware, Ohio

Grady Memorial Hospital, Delaware, Ohio

Hematology Oncology Center Incorporated, Elyria, Ohio

Mercy Cancer Center-Elyria, Elyria, Ohio

Oncology Hematology Care Inc-Healthplex, Fairfield, Ohio

Blanchard Valley Hospital, Findlay, Ohio

Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio

Wayne Hospital, Greenville, Ohio

Cleveland Clinic Cancer Center Independence, Independence, Ohio

Kettering Medical Center, Kettering, Ohio

Fairfield Medical Center, Lancaster, Ohio

Lancaster Radiation Oncology, Lancaster, Ohio

Saint Rita's Medical Center, Lima, Ohio

Lima Memorial Hospital, Lima, Ohio

OhioHealth Mansfield Hospital, Mansfield, Ohio

Cleveland Clinic Cancer Center Mansfield, Mansfield, Ohio

Marietta Memorial Hospital, Marietta, Ohio

Saint Luke's Hospital, Maumee, Ohio

Toledo Clinic Cancer Centers-Maumee, Maumee, Ohio

Toledo Radiation Oncology at Northwest Ohio Onocolgy Center, Maumee, Ohio

Hillcrest Hospital Cancer Center, Mayfield Heights, Ohio

UH Seidman Cancer Center at Landerbrook Health Center, Mayfield Heights, Ohio

UH Seidman Cancer Center at Lake Health Mentor Campus, Mentor, Ohio

UH Seidman Cancer Center at Southwest General Hospital, Middleburg Heights, Ohio

Knox Community Hospital, Mount Vernon, Ohio

Licking Memorial Hospital, Newark, Ohio

Newark Radiation Oncology, Newark, Ohio

Fisher-Titus Medical Center, Norwalk, Ohio

Saint Charles Hospital, Oregon, Ohio

Toledo Clinic Cancer Centers-Oregon, Oregon, Ohio

Southern Ohio Medical Center, Portsmouth, Ohio

North Coast Cancer Care, Sandusky, Ohio

UH Seidman Cancer Center at Firelands Regional Medical Center, Sandusky, Ohio

Springfield Regional Medical Center, Springfield, Ohio

Trinity's Tony Teramana Cancer Center, Steubenville, Ohio

Cleveland Clinic Cancer Center Strongsville, Strongsville, Ohio

ProMedica Flower Hospital, Sylvania, Ohio

Mercy Hospital of Tiffin, Tiffin, Ohio

ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo, Ohio

Mercy Health - Saint Vincent Hospital, Toledo, Ohio

University of Toledo, Toledo, Ohio

Toledo Community Hospital Oncology Program CCOP, Toledo, Ohio

Mercy Health - Saint Anne Hospital, Toledo, Ohio

Toledo Clinic Cancer Centers-Toledo, Toledo, Ohio

Upper Valley Medical Center, Troy, Ohio

University Hospitals Sharon Health Center, Wadsworth, Ohio

South Pointe Hospital, Warrensville Heights, Ohio

Fulton County Health Center, Wauseon, Ohio

University of Cincinnati Cancer Center-West Chester, West Chester, Ohio

Saint Ann's Hospital, Westerville, Ohio

UH Seidman Cancer Center at Saint John Medical Center, Westlake, Ohio

Clinton Memorial Hospital/Foster J Boyd Regional Cancer Center, Wilmington, Ohio

Cleveland Clinic Wooster Family Health and Surgery Center, Wooster, Ohio

Wright-Patterson Medical Center, Wright-Patterson Air Force Base, Ohio

Greene Memorial Hospital, Xenia, Ohio

Genesis Healthcare System Cancer Care Center, Zanesville, Ohio

Conditions: HER2/Neu Positive, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7

Learn More ›

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

NCT03645928

Recruiting

A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL \[LN-144/LN-145 (lifileucel)\] in combination with immune checkpoint inhibitors or TIL \[LN-144/LN-145 (lifileucel) and LN-145-S1\] as a single agent therapy.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/18/2025

Locations: University of Cincinnati, Cincinnati, Ohio +1 locations

Conditions: Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer

Learn More ›

Browse Paclitaxel Treatment Options in Other Ohio Cities

Paclitaxel treatment options in Columbus

Paclitaxel treatment options in Cleveland